C
Commodore Capital LP
+ HoldingCDTX
+32.18%
3M Return
$221.380
+0.066 (+0.03%)Al cierre
Loading chart…
- High
- 221.410
- Open
- 221.320
- VWAP
- 221.35
- Vol
- 2.69M
- Mkt Cap
- 51.05M
- Low
- 221.250
- Amount
- 595.65M
- EV/EBITDA, TTM
- -27.12
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Analyst Ratings (9)
-5.29% downside
Buy
8 Buy
1 Hold
0 Sell
Current: 221.38
Mínimo
173.00
Promedio
209.67
Máximo
221.50
Guggenheim
Neutral
—
2025-11-17
Guggenheim
2025-11-17
Precio objetivo
—
Neutral
BofA
Buy
$105
2025-11-17
BofA
2025-11-17
Precio objetivo
$105
Buy
Morgan Stanley
Equal Weight
$221.50
2025-11-16
Morgan Stanley
2025-11-16
Precio objetivo
$221.50
Equal Weight
H.C. Wainwright
Neutral
—
2025-11-14
H.C. Wainwright
2025-11-14
Precio objetivo
—
Neutral
Needham
Hold
—
2025-11-14
Needham
2025-11-14
Precio objetivo
—
Hold
Métricas de valoración
The current forward P/E ratio for Cidara Therapeutics Inc (CDTX) is -27.50, compared to its 5-year average forward P/E of -4.67.
Whales holding CDTX
Cronología de eventos
Noticias
8.501-09BenzingaMerck in Talks to Acquire Revolution Medicines for $28-32 Billion
7.501-02NASDAQ.COMHighVista Initiates Position in Cidara with 70,904 Shares Worth $6.79 Million
7.501-02FoolHighVista Strategies Acquires $6.79M Stake in Cidara Therapeutics
9.512-31NASDAQ.COMPalvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
8.012-19NASDAQ.COMSignificant Friday Options Trading: CDTX, STZ, LRCX
CDTX FAQ — answered by Alphio AI
Cidara Therapeutics, Inc. is a biotechnology company. The Company is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The Company is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
9 analysts cover CDTX: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 209.67.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.